Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

Digoxin now deserves to be considered first-line therapy for long-term heart rate control in older patients with permanent atrial fibrillation and symptoms of heart failure, investigators on a new ...

Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

UB researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin. The breakthrough ...

"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

MADRID -- Digitoxin added to guideline-directed medical therapy improved outcomes among patients with heart failure and reduced ejection fraction (HFrEF), the DIGIT-HF trial showed. The cardiac ...

A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...

At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, a cardiac glycoside associated in modern medicine with Digitalis species ...

Heart drugs called digitalis glycosides, which include digoxin and digitoxin, have been used for centuries, but their place in the modern treatment of heart failure remains undefined. Results were ...